Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.68
-3.7%
$0.80
$0.61
$3.02
$32.19M3.04609,658 shs1.24 million shs
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
$7.63
+9.6%
$7.11
$2.81
$23.01
$8.01M0.2556,380 shs377,941 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$1.19
+10.2%
$1.29
$1.04
$4.40
$27.74M1.1358,840 shs41,191 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.44
-0.2%
$0.45
$0.30
$4.28
$30.08M-0.041.66 million shs785,993 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+2.10%+12.17%-8.29%-28.46%-32.81%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.00%0.00%-12.40%+27.38%+125.74%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-9.24%-21.17%-8.47%-42.55%+107,999,900.00%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-0.52%-0.83%-3.67%-38.99%-65.92%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.68
-3.7%
$0.80
$0.61
$3.02
$32.19M3.04609,658 shs1.24 million shs
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
$7.63
+9.6%
$7.11
$2.81
$23.01
$8.01M0.2556,380 shs377,941 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$1.19
+10.2%
$1.29
$1.04
$4.40
$27.74M1.1358,840 shs41,191 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.44
-0.2%
$0.45
$0.30
$4.28
$30.08M-0.041.66 million shs785,993 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+2.10%+12.17%-8.29%-28.46%-32.81%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.00%0.00%-12.40%+27.38%+125.74%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-9.24%-21.17%-8.47%-42.55%+107,999,900.00%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-0.52%-0.83%-3.67%-38.99%-65.92%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.001,218.68% Upside
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.00
N/AN/AN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
2.00
HoldN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.14
Buy$5.201,075.67% Upside

Current Analyst Ratings Breakdown

Latest PRTG, ITRM, RVPH, and RNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
8/18/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00 ➝ $3.00
8/18/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
8/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$5.00 ➝ $2.00
6/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/AN/AN/A($0.79) per shareN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/A$0.45 per share2.66$0.43 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.85N/AN/AN/AN/A-65.01%11/13/2025 (Estimated)
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
-$6.77M-$41.65N/AN/AN/AN/AN/A9/15/2025 (Estimated)
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)

Latest PRTG, ITRM, RVPH, and RNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$0.22-$0.28-$0.06-$0.28N/AN/A
8/14/2025Q2 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.15-$0.12+$0.03-$0.12N/AN/A
8/5/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13-$0.16-$0.03-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/AN/AN/AN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.69
2.52
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/A
2.02
2.02
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A
0.86
0.86
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.90
0.90

Institutional Ownership

CompanyInstitutional Ownership
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
13.36%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
90.89%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.40%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
42.07%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
5.10%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1047.17 million46.04 millionNot Optionable
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
61.05 million608,000Optionable
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
923.31 million22.12 millionN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
568.00 million49.52 millionOptionable

Recent News About These Companies

RVPH: There May Be A Faster Way
Reviva Narrows Loss 23% in Fiscal Q2
Reviva Dives on Stock Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.68 -0.03 (-3.72%)
Closing price 03:59 PM Eastern
Extended Trading
$0.67 -0.01 (-1.83%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Portage Biotech stock logo

Portage Biotech NASDAQ:PRTG

$7.63 +0.67 (+9.63%)
Closing price 09/3/2025
Extended Trading
$7.63 0.00 (0.00%)
As of 09/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$1.19 +0.11 (+10.19%)
As of 03:59 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.44 0.00 (-0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$0.44 0.00 (-0.07%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.